COX-2抑制剂治疗良性前列腺增生症引起夜尿症的临床研究  

Effect of cyclooxygenase-2 inhibitor in the treatment of nocturia caused by benign prostatic hyperplasia

作　　者：左立[1] 李寿春[1] 邹建纲[1] 周忠兴[1] 吴小鹏[1] 陆曙炎[1] 

机构地区：[1]南京医科大学附属常州市第二人民医院,常州213003

出　　处：《上海医药》2012年第23期15-17,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的：研究COX-2抑制剂对BPH患者发生夜尿症的疗效。方法：100名患有良性前列腺增生症的患者，平均年龄67岁（59～79岁），均有夜尿频的症状，并且夜尿次数〉2次，均服用仪受体阻滞剂，但夜尿症改善不明显，随机分为两组：一组给予100mg塞来昔布每晚口服；另一组给予100mg安慰剂每晚口服，总共持续2周。对比两组服药前后夜尿症改善情况。结果：服用COX-2抑制剂组后，平均夜尿次数由（6．05±2-3）次／晚降为（2．4±1．8）次／晚（P〈0．01）；安慰剂组服药前平均夜尿次数为（6．13±2．1）次／晚，服药后为（5．82±2．8）次／晚（P〉0．05）。未发现COX-2抑制剂有明显的不良反应。结论：COX-2抑制剂对患有难治性夜尿症的BPH患者是有效安全的。Objective： To estimate the efficacy of celecoxib, a cyclooxygenase-2 inhibitor, in the treatment of patients with BPH complaining of nocturia. Methods： We assessed 100 BPH patients with symptoms of nocturia at average age 67 （59-79）. Among them, the nocturnal frequency should be more than 2, associated with the failure treatment of alpha-blocker. They were randomly divided into two groups： experimental group was received 100 mg of celecoxib at 9 PM for 2 weeks and control group was treated with placebo. Results： The nocturnal frequency was decreased from （6.05 ± 2.3） to （2.4 ±1.8） （P〈0.01） in experimental group with no significant side effects observed. Conclusion： Cyclooxygenase-2 inhibitor is effective in treatment of patients with BPH complaining of refractory nocturia.

关 键 词：COX-2抑制剂 疗效 良性前列腺增生症 夜尿症 

分 类 号：R697.3[医药卫生—泌尿科学]